Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Studies from National Institute of Health and Nutrition have provided new data on cancer gene therapy
May 20th, 2008
Researchers detail in '5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene,' new data in cancer gene therapy. "The connexin (Cx) 32 gene, a member of the gap junction gene family, acts as a tumor suppressor gene in human renal cell carcinoma (RCC) and is down-regulated by the hypermethylation of CpG islands in a promoter region of the Cx gene. The current study investigated whether the restoration of Cx32 silenced by hypermethylation in RCC by a DNA demethylating agent could be an effective treatment against RCC," investigators in Shinjuku, Japan report. "EXPERIMENTAL APPROACH: Using nude...
Source: Cancer Weekly (2008-05-20)
|
